Fisetin plus exercise versus placebo in breast cancer survivors for frailty prevention: phase II RCT
This phase II randomized controlled trial tested fisetin (a dietary compound found in strawberries) combined with exercise against placebo for preventing frailty in breast cancer survivors. The trial was designed to evaluate whether fisetin could eliminate senescent cells—aged cells that stop dividing but persist in tissues—which are hypothesized to contribute to frailty through inflammatory pathways.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 30, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Breast cancer survivors
- Primary outcome
- Prevention of frailty in breast cancer survivors
- Effect size
- —
- Significance
- Not reported
- Journal
- Jonsson Comprehensive Cancer Center
- Published
- Jul 30, 2026
Sources
Primary source
- Jonsson Comprehensive Cancer Center ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.